Cencora Biosimilars Chiefs Talk Adalimumab Pricing, Interchangeability And The IRA
Executives From Former AmerisourceBergen Firm Discuss Latest US Biosimilars Developments
Executive Summary
With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.